News Articles Tagged: Deucravacitinib Mechanism

The Science Behind Deucravacitinib: Mechanism of Action and Selectivity

Delve into the molecular intricacies of Deucravacitinib, understanding its selective allosteric inhibition of TYK2 and its impact on inflammatory pathways.

Deucravacitinib (BMS-986165): A Paradigm Shift in Treating Autoimmune Diseases

Explore how Deucravacitinib, a selective TYK2 inhibitor, is creating a paradigm shift in managing autoimmune diseases by targeting specific inflammatory pathways. Learn about its advantages and applications.

The Science Behind Deucravacitinib: A Deep Dive into TYK2 Inhibition for Autoimmune Diseases

Explore the innovative mechanism of Deucravacitinib (BMS-986165), a first-in-class oral TYK2 inhibitor, and its impact on treating plaque psoriasis and other autoimmune conditions. Understand the science driving this breakthrough therapy.